9 Použitá literatura

Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992;71:206–215.

Altrichter S, Zampeli V, Ellrich A, et al. IgM and IgA in addition to IgG autoantibodies against FcεRIα are frequent and associated with disease markers of chronic spontaneous urticaria [published online ahead of print, 2020 May 23]. Allergy 2020;10.

Andersen MF, Longhurst HJ, Rasmussen ER, et al. How not to be misled by disorders mimicking angioedema: a review of pseudoangioedema. Int Arch Allergy Immunol 2016;169:163–170.

Baffert F, Le T, Thurston G, et al. Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules. Am J Physiol Heart Circ Physiol 2006;290:107–118.

Bafunno V, Firinu D, D'Apolito M, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol 2018;141:1009–1017.

Banday AZ, Kaur A, Jindal AK, et al. An update on the genetics and pathogenesis of hereditary angioedema. Genes Dis 2019;7:75–83.

Banerji A, Blumenthal KG, Lai KH, et al. Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. J Allergy Clin Immunol Pract 2017;5:744–749.

Banerji A, Li Y, Busse P, et al. Hereditary angioedema from the patient's perspective: a follow-up patient survey. Allergy Asthma Proc 2018;39:212–223.

Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA 2018;320:2108–2121.

Baş M, Greve J, Stelter K, et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 2015;372:418–425.

Benáková N. Současné praktické postupy pro vyšetřování a léčbu chronické urtikarie. Aktualizovaný přehled a interpretace doporučených postupů pro praxi. Čes Slov Derm 2015;5:179–193

Bennett G, Craig T. Hereditary angioedema with a focus on the child. Allergy Asthma Proc 2015;36:70–73.

Betschel S, Badiou J, Binkley K, et al. The International/Canadian Hereditary Angioedema Guideline. Allergy Asthma Clin Immunol 2019;15:72. Erratum in: Allergy Asthma Clin Immunol 2020;16:33.

Bernstein JA, Cremonesi P, Hoffmann TK, et al. Angioedema in the emergency department: a practical guide to differential diagnosis and management. Int J Emerg Med 2017;10:15.

Bernstein J, Moldovan D, Hakl R, et al. Experience with recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy. Ann Allergy Asthma Immunol 2018;121(Suppl):S33.

Björkqvist J, de Maat S, Lewandrowski U, et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 2015;125:3132–3146.

Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119:267.

Bork K, Staubach-Renz P, Hardt J. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate. Orphanet J Rare Dis 2019;14:65.

Bork K, Wulff K, Rossmann H, et al. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin. Allergy 2019;74:2479–2481.

Bork K, Wulff K, Witzke G, et al. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. Allergy 2015;70:1004–1012.

Bork K, Wulff K, Witzke G, et al. Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII). Allergy 2017;72:320–324.

Bork K, Wulff K, Witzke G, et al. Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene. Orphanet J Rare Dis 2020;15:52.

Bork K, Zibat A, Ferrari DM, et al. Hereditary angioedema in a single family with specific mutations in both plasminogen and SERPING1 genes. J Dtsch Dermatol Ges 2020;18:215–223.

Bouillet L, Launay D, Fain O, et al. Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. Ann Allergy Asthma Immunol 2013;111:290–294.

Busse P, Bygum A, Edelman J, et al. Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry. J Allergy Clin Immunol Pract 2015;3:213–219.

Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med 2020;382:1136–1148.

Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 2008;51:141–147.

Caballero T, Farkas H, Bouillet L, et al. C-1-INH Deficiency Working Group. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012;129:308–320.

Campbell DJ. Neprilysin inhibitors and bradykinin. Front Med (Lausanne) 2018;5:257.

Carlson G, Coop C. Pollen food allergy syndrome (PFAS): A review of current available literature. Ann Allergy Asthma Immunol 2019;123:359–365.

Cicardi M, Aberer W, Banerji A, et al. HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014;69:602–616.

Cicardi M, Suffritti C, Perego F, et al. Novelties in the diagnosis and treatment of angioedema. J Investig Allergol Clin Immunol 2016;26:212–221.

Cicardi M, Zuraw BL. Angioedema due to bradykinin dysregulation. J Allergy Clin Immunol Pract 2018;6:1132–1141.

Craig T, Zuraw B, Longhurst H, et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. J Allergy Clin Immunol Pract 2019;7:1793–802.e2.

Csuka D, Veszeli N, Varga L, et al. The role of the complement system in hereditary angioedema. Mol Immunol 2017;89:59–68.

Češka R, a kol. Interna. 3. aktualizované vydání. Triton: Praha, 2020; s. 230–241.

Demirturk M, Gelincik A, Cinar S, et al. Increased eNOS levels in hereditary angioedema. Int Immunopharm 2014;20:264–268.

Depetri F, Tedeschi A, Cugno M. Angioedema and emergency medicine: from pathophysiology to diagnosis and treatment. Eur J Intern Med 2019;59:8–13.

Deroux A, Boccon-Gibod I, Fain O, et al. Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema. Clin Exp Immunol 2016;185:332–337.

Dobo J, Major B, Kekesi KA, et al. Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1. PLoS One 2011;6:e20036.

Duerr M, Glander P, Diekmann F, et al. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010;5:703–708.

Dubrall D, Schmid M, Stingl JC, et al. Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports. PLoS One 2020;15:e0230632.

Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol 2010;6:18.

Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency HAWK. Allergy 2017;72:300–313.

Gavorník P, Dukát A, Gašpar L, et al. Diagnóza a manažment angioedému. Kardiol Rev Int Med 2018;20:286–293.

Gobert D, Paule R, Ponard D, et al. A nationwide study of acquired C1-inhibitor deficiency in France: Characteristics and treatment responses in 92 patients. Medicine (Baltimore) 2016;95:e4363

Gruber BL, Baeza ML, Marchese MJ, et al. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988;90:213–217.

Hahn J, Hoffmann TK, Bock B, et al. Angioedema. Dtsch Arztebl Int 2017;114:489–496.

Hakl R. Current treatment options for hereditary angioedema. Vnitr Lek 2016;62:736–739.

Hakl R, Kuklínek P, Krčmová I, et al. Treatment of hereditary angioedema attacks with icatibant and recombinant C1 inhibitor during pregnancy. J Clin Immunol 2018;38:810–815.

Haslund D, Ryø LB, Seidelin Majidi S, et al. Dominant-negative SERPING1 variants cause intracellular retention of C1 inhibitor in hereditary angioedema. J Clin Invest 2019;129:388–405.

Haymore BR, Yoon J, Mikita CP, et al. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol 2008;101:495–499.

Henao MP, Kraschnewski JL, Kelbel T et al. Diagnosis and screening of patients with hereditary angioedema in primary care. Ther Clin Risk Manag 2016;12:701–711.

Hurford R, Rezvani S, Kreimei M, et al. Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke. J Neurol Neurosurg Psychiatry 2015;86:520–523.

Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 2015;135:337–342.

Ivanov I, Matafonov A, Sun MF, et al. A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain. Blood 2019;133:1152–1163.

Janardhanan D, Nair S, Subramanian TS. Recurrent abdominal pain due to hereditary angioedema. Indian J Pediatr 2007;74:83–84.

Klauzová K. Diagnostika a léčba lymfedému. Interní Med 2010;12:36–40.

Konstantinou GN, Asero R, Maurer M, et al. EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy 2009;64:1256–1268.

Kowalski ML, Makowska JS. Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice? Allergy Asthma Immunol Res 2015;7:312–320.

Krčmová I. Hereditární angioedém – trendy v léčbě. Interní Med 2017;19:131–137.

Kuklínek P, Hanzlíková J. Hereditární angioedém. Praha: Medical Tribune CZ, 2013; 74 s.

Kusuma A, Relan A, Knulst AC, et al. Clinical impact of peripheral attacks in hereditary angioedema patients. Am J Med 2012;125:937.e17–24.

Longhurst H, Zinser E. Prophylactic therapy for hereditary angioedema. Immunol Allergy Clin North Am 2017;37:557–570.

Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension 2006;48:846–852.

Machovcová A. Kontaktní dermatitidy. Med pro Praxi 2018;5:325–328.

Malbran A, Riedl M, Ritchie B, et al. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. Clin Exp Immunol 2014;177:544–553.

Martinez-Saguer I, Farkas H. Erythema marginatum as an early symptom of hereditary angioedema: case report of 2 newborns. Pediatrics 2016;137:e20152411

Maurer M, Eyerich K, Eyerich S, et al. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. Int Arch Allergy Immunol 2020;181:321–333.

Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. World Allergy Organization J 2018;11:5.

McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013;15:1062–1073.

Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004;10:499–509.

Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966;3:331–333.

Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014;69:1026–1045.

Nedelea I, Deleanu D. Isolated angioedema: an overview of clinical features and etiology. Exp Ther Med 2019;17:1068–1072.

Nguyen A, Zuraw BL, Christiansen SC. Contact system activation during erythema marginatum in hereditary angioedema. Ann Allergy Asthma Immunol 2020;124:394–395.

Qadri F, Bader M. Kinin B1 receptors as a therapeutic target for inflammation. Expert Opin Ther Targets 2018;22:31–44.

Renné T, Stavrou EX. Roles of factor XII in Innate Immunity. Front Immunol 2019;10:2011.

Reshef V, Grivcheva-Panovska V, Kessel A, et al. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. Pediatr Allergy Immunol 2019;30:562–568.

Riedl MA, Bygum A, Lumry W, et al. Safety and usage of C1-inhibitor in hereditary angioedema: Berinert registry data. J Allergy Clin Immunol Pract 2016;4:963–971.

Riedl MA, Grivcheva-Panovska V, Moldovan D, et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet 2017;390:1595–1602.

Saavedra MC, Sur S. Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clin Mol Allergy 2011;9:2.

Sanini S. Acquired C1 inhibitor deficiency: management and prognosis [online]. Up-to-date [cit. 3. 11. 2020]. Dostupné na: https://www-uptodate-com.ezproxy.is.cuni.cz/contents/acquired-c1-inhibitor--deficiency-management-and-prognosis?search=acquired c1 inhibitor deficiency&source=search_result&selectedTitle=2~35&usage_type=default&display_rank=2

Sanini S. Hereditary angioedema: epidemiology, clinical manifestations, exacerbating factors, and prognosis [online]. Up-to-date [cit. 30. 10. 2020]. Dostupné na: https://www.uptodate.com/contents/hereditary-angioedema-epidemiology--clinical-manifestations-exacerbating-factors-and-prognosis?search==acquired%20C1%20inhibitor&topicRef=8112&source=see_link

Settipane RA, Bukstein D, Riedl M. Shared decision making in HAE management. Allergy Asthma Proc 2020;41:S55–S60.

Scheirey CD, Scholz FJ, Shortsleeve MJ, et al. Angiotensin-converting enzyme inhibitor-induced small-bowel angioedema: clinical and imaging findings in 20 patients. AJR Am J Roentgenol 2011;197:393–398.

Schwartz LB. Laboratory tests to support the clinical diagnosis of anaphylaxis [online]. Up-to-date [cit. 10. 11. 2020]. Dostupné na: https://www-uptodate-com.

ezproxy.is.cuni.cz/contents/laboratory-tests-to-support-the-clinical-diagnosis-of-anaphylaxis?search=angioedema&topicRef=8105&source=see_link

Sinert R, Levy P, Bernstein JA, et al. Randomized trial of icatibant for angiotensin-converting enzyme inhibitor-induced upper airway angioedema. J Allergy Clin Immunol Pract 2017;5:1402–1409.e3.

Staršia Z, Hegyi E, Kuklínek P, et al. Hereditary angioedema in Czechoslovakia. Clinical, immunological, genetic and therapeutic studies of 16 families. Allerg Immunol (Leipz) 1988;34:35–42.

Staršia Z, Štefanovič J, Čáp J, et al. Deficiencia Inhibitora C1-esterázy u pacientky s dědičným angioneurotickým edémom. Čas Lék Čes 1975;5:1255–1258.

Stolz LE, Horn PT. Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema. Drugs Today (Barc) 2010;46:547–555.

Vachová M. Anafylaxe – akutní a dlouhodobý management. Vnitř Lek 2020;66:335–339.

Valerieva A, Senter R, Wu MA, et al. Lanadelumab for the prevention of attacks in hereditary angioedema. Expert Rev Clin Immunol 2019;15:1239–1248.

Valerieva A, Staevska M, Jesenak M, et al. Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract 2020;8:799–802.

Wedner J. Hereditary angioedema: pathophysiology (HAE type I, type II, and HAE nC1-INH). Allergy Asthma Proc 2020;41:14–17.

Wentzel N, Panieri A, Ayazi M, et al. Fresh frozen plasma for on-demand hereditary angioedema treatment in South Africa and Iran. World Allergy Organ J 2019;12:100049.

Wu MA, Perego F, Zanichelli A, Cicardi M. Angioedema phenotypes: disease expression and classification. Clin Rev Allergy Immunol 2016;51:162–169.

Yu L, Buttgereit T, Stahl Skov P, et al. Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2019;33:1747–1754.

Zhang B, Li Q, Shi C, Zhang X. Drug-induced pseudoallergy: a review of the causes and mechanisms. Pharmacology 2018;101:104–110.

Zingale LC, Castelli R, Zanichelli A, et al. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am 2006;26:669–690.

Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73:1393–1414.

Zuraw B. An overview of angioedema: Clinical features, diagnosis and management [online]. Up-to-date [cit. 3. 11. 2020]. Dostupné na: https://www-uptodate-com.ezproxy.is.cuni.cz/contents/an-overview-of--angioedema-clinical-features-diagnosis-and-management?search==angioedema&source=search_result&selectedTitle=1~150&usage_type==default&display_rank=1

Zuraw B. An overview of angioedema: pathogenesis and causes [online]. Up-to-date [cit. 3. 11. 2020]. Dostupné na: https://www-uptodate-com.ezproxy.is.cuni.cz/contents/an-overview-of--angioedema-pathogenesis-and-causes?search=angioedema&source==search_result&selectedTitle=2~150&usage_type=default&display_rank=2

Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513–522.

Zuraw BL, Davis DK, Castaldo AJ, et al. Tolerability and effectiveness of 17-alpha-alkylated androgen therapy for hereditary angioedema: a re-examination. J Allergy Clin Immunol Pract 2016;4:948–955.

Hereditární angioedém – Doporučený postup ČSAKI [online]. Dostupné na: https://www.csaki.cz/dokumenty/HAE_dopor_postup.pdf

Lanadelumab Overview [online]. Dostupné na: https://www.creativebiolabs.net/lanadelumab-overview.htm

Informace o přípravku Xolair [online]. Státní ústav pro kontrolu léčiv [cit. 12. 11. 2020]. Dostupné na: www.sukl.cz